Research Analysts Issue Forecasts for ACRV FY2025 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Acrivon Therapeutics in a report released on Tuesday, November 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($2.02) per share for the year, up from their previous estimate of ($2.17). The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. Cantor Fitzgerald also issued estimates for Acrivon Therapeutics’ FY2026 earnings at ($1.44) EPS.

A number of other brokerages also recently weighed in on ACRV. Oppenheimer lowered their target price on shares of Acrivon Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Thursday, August 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Acrivon Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Acrivon Therapeutics Stock Down 4.2%

Shares of Acrivon Therapeutics stock opened at $2.26 on Thursday. The stock has a market cap of $71.33 million, a P/E ratio of -1.06 and a beta of 1.82. Acrivon Therapeutics has a 12-month low of $1.05 and a 12-month high of $8.00. The business’s 50 day moving average is $1.91 and its 200-day moving average is $1.50.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.10.

Institutional Investors Weigh In On Acrivon Therapeutics

Hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth bought a new stake in shares of Acrivon Therapeutics during the third quarter worth approximately $36,000. Algert Global LLC acquired a new stake in Acrivon Therapeutics during the 3rd quarter worth approximately $81,000. Two Sigma Investments LP boosted its stake in Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock valued at $578,000 after purchasing an additional 138,033 shares during the period. UBS Group AG boosted its stake in Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after purchasing an additional 682,763 shares during the period. Finally, Jane Street Group LLC acquired a new position in Acrivon Therapeutics in the 2nd quarter valued at $371,000. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.